NEW YORK, Feb. 20, 2025 /PRNewswire/ — Rightway, the only PBM purpose-built for transparency and fiduciary alignment, today released its 2024 PBM Annual Report, showcasing another year of record-breaking growth, significant cost savings for clients, and groundbreaking advancements in member experience and clinical excellence.
In a year when traditional PBMs faced growing backlash and increased FTC scrutiny over hidden fees and conflicts of interest, Rightway delivered real savings and better care.
Key results:
Clinical excellence.
Rightway is the only PBM that embeds pharmacy navigation into every member interaction, ensuring members receive proactive, pharmacist-led support. 100% of Rightway’s care team is made up of clinical pharmacists and pharmacy technicians, so members get real guidance—not automated call center scripts. In 2024, 53% of member interactions were with a pharmacist, underscoring Rightway’s deep commitment to clinically driven pharmacy benefits.
“Rightway is delivering the only pharmacy benefit built for employers and members—not hidden profits,” said Jordan Feldman, Co-Founder and CEO at Rightway. “We’re putting control back in the hands of plan sponsors while ensuring members get the best care and lowest-cost medications. Our clients trust us to optimize costs without hidden fees, misaligned incentives, or unnecessary complexity of the other guys.”
Scaling smarter with innovative solutions.
Leading innovation.
Rightway is redefining what innovation in pharmacy benefits truly means by going beyond surface-level tech to deliver real cost savings, smarter pricing models, and greater control for employers and members. In 2024, Rightway introduced several new products and initiatives:
Implementation done right.
Rightway’s well-managed implementation process delivered a smooth experience for 2025 launches and enabled Rightway to launch a leading global shipping company in just three months. Operational expertise and modern technology took the headache out of implementation, leading to 100% of new clients reporting being “very satisfied” with implementation.
What’s ahead in 2025.
As FTC scrutiny on PBMs intensifies, employers and patients alike are seeking transparency and control. Rightway delivers exactly that: 100% rebate pass-through, zero hidden markups, and an auditable PMPM pricing model. Unlike traditional PBMs that profit from rebates and spread pricing, Rightway was built to align with employers, not exploit them.
Read the full 2024 Annual PBM Report here to learn more about how Rightway is driving the future of pharmacy benefits.
Join our webinar on March 12th to hear directly from Rightway leadership and get an inside look at the strategies driving our success.
About Rightway:
Rightway is transforming pharmacy benefits and healthcare navigation with a member-first approach that combines unmatched service with expert clinical guidance and advanced, intuitive technology. Serving over two million members, Rightway delivers personalized, evidence-based support that reduces costs, improves outcomes, and drives measurable engagement. As the first PBM to offer fully aligned, pass-through pricing backed by a total spend guarantee, Rightway ensures measurable, dollar-for-dollar savings. With unmatched fiduciary alignment, Rightway secures the best prescription prices without hidden fees or conflicts of interest, delivering true transparency and value. Rightway Care Navigation helps members make smarter, cost-effective care choices, backed by analytics and dedicated health guides, driving measurable outcomes. Over 1,500 clients trust Rightway for its innovative solutions and exceptional client services. For more information, visit www.rightwayhealthcare.com.
Rightway contact:
Rita Lebedeva, SVP of Marketing
info@rightwayhealthcare.com
SOURCE Rightway
SEATTLE, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage…
– Data support initiation of a combination cohort in the ongoing Phase 1 clinical trial…
SPRING, Texas, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Io Therapeutics, Inc., a privately held pharmaceutical…
Ficerafusp alfa 750mg QW in combination with pembrolizumab demonstrates consistent overall response rate and safety…
TUS+VEN+AZA triplet frontline therapy demonstrates high rates of efficacy and MRD-negative remissions in newly diagnosed…
Demonstrated meaningful overall anemia responses across all patient subgroups, regardless of baseline transfusion status Anemia response…